Tirzepatide
Mounjaro / Zepbound analog
Mechanism of Action
Dual GLP-1 and GIP receptor agonist (twincretin). GIP action synergizes with GLP-1 for superior weight loss and glycemic control versus semaglutide monotherapy.
Key Benefits
- Superior weight loss vs semaglutide (~20–22% in SURMOUNT trials)
- Improved insulin sensitivity and beta-cell function
- Favorable lipid profile changes
- Reduced HbA1c in T2D populations
Dosing Protocol
Titrate every 4 weeks. Superior to semaglutide in head-to-head weight loss data.
Ideal Candidates
Adults with T2D or obesity. Strong candidate for those who plateaued on semaglutide.
Side Effects & Safety
Nausea, vomiting, diarrhea (GLP-1 class). Generally well-tolerated with slow titration.
Regulatory Status
Gray AreaFDA shortage resolved; compounding window is closing. Monitor eligibility with pharmacy counsel.
Frequently asked
What is Tirzepatide?+
Tirzepatide (Mounjaro / Zepbound analog) is a peptide studied for superior weight loss and dual receptor action. Dual GLP-1 and GIP receptor agonist (twincretin). GIP action synergizes with GLP-1 for superior weight loss and glycemic control versus semaglutide monotherapy.
What is the dosing protocol for Tirzepatide?+
Literature commonly references 2.5 mg/wk (low) to 10 mg/wk (maintenance) via SubQ weekly, on a ongoing cycle. Educational reference only — a licensed Stackhaus Health provider sets any personalized protocol.
What is the regulatory status of Tirzepatide?+
FDA shortage resolved; compounding window is closing. Monitor eligibility with pharmacy counsel.
Where can I access Tirzepatide?+
Research-grade Tirzepatide is available through Stackhaus Research. For a personalized, provider-reviewed protocol, consult a licensed clinician through Stackhaus Health.